Radnostix, Inc.
INIS · Other OTC · USD
0,05USD
+0,01 (+25,00 %)Stand 11. Nov., 21:00
Kennzahlen
- Eröffnung
- 0,0409
- Vortag
- 0,04
- Tagesspanne
- 0,0385 – 0,05
- 52 Wochen
- 0,03 – 0,10
- Volumen
- 12.500
- Ø Volumen
- 59.408
- Börsenwert
- 26,46 Mio. $
- KGV
- -0,0
- Gewinn je Aktie (TTM)
- -1.723,63
- Dividendenrendite
- 0,0 %
- Beta
- 1,4
- Nächste Zahlen
- –
Finanzen
| USD | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Umsatz | 13,07 Mio. | 13,9 Mio. | 12,27 Mio. | 11,18 Mio. | 9,66 Mio. |
| Herstellungskosten | 9,86 Mio. | 5,25 Mio. | 4,89 Mio. | 4,89 Mio. | 3,92 Mio. |
| Bruttogewinn | 3,21 Mio. | 8,65 Mio. | 7,38 Mio. | 6,29 Mio. | 5,74 Mio. |
| Forschung und Entwicklung | 435,84 Mrd. | 610.737 | 577.354 | 533.716 | 271.714 |
| Vertrieb und Verwaltung | 3,73 Bio. | 4,01 Mio. | 7,58 Mio. | 6,96 Mio. | 6,15 Mio. |
| Operatives Ergebnis | −956.187 | 6901 | −776.299 | 917.181 | 2572 |
| EBITDA | −76.032 | 738.319 | −187.142 | 1,29 Mio. | 607.835 |
| Nettogewinn | −908.000 | 8574 | −869.016 | −310.705 | −2,38 Mio. |
| Gewinn je Aktie (verwässert) | -0,00 | 0,00 | -0,00 | -0,00 | -0,01 |
Umsatz nach Segment
Produkte · FY 2025
- Cobalt Products1,75 Mio. $100,00 %
Anteil · ggü. Vorjahr (FY –)
Bewertung
Letzte 12 Monate
- KGV
- -0,0
- Kurs-Umsatz-Verhältnis
- 2,4
- Kurs-Buchwert-Verhältnis
- 14,0
- PEG
- -0,0
- Bruttomarge
- 31,7 %
- Operative Marge
- −25,8 %
- Nettomarge
- −8.087.807,2 %
- Verschuldungsgrad
- 4,9
- EV/EBITDA
- -16,0
- Eigenkapitalrendite
- −29.463.464,9 %
- Kapitalrendite (ROIC)
- −22,7 %
- Free-Cashflow-Rendite
- −3,5 %
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Bruttomarge | 24,6 % | 62,2 % | 60,2 % | 56,3 % | 59,4 % |
| Operative Marge | −7,3 % | 0,0 % | −6,3 % | 8,2 % | 0,0 % |
| Nettomarge | −6,9 % | 0,1 % | −7,1 % | −2,8 % | −24,6 % |
| KGV | -36,0 | 2.095,5 | -23,5 | -54,2 | -18,0 |
| Kurs-Umsatz-Verhältnis | 2,5 | 1,3 | 1,7 | 1,5 | 4,4 |
| Kurs-Buchwert-Verhältnis | 8,7 | 4,1 | 5,1 | 3,8 | 15,7 |
| Verschuldungsgrad | 1,3 | 1,9 | 2,1 | 0,9 | 1,6 |
| Liquidität 3. Grades | 1,2 | 1,5 | 1,8 | 1,6 | 0,7 |
| Dividendenrendite | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Unternehmenswert | 35,41 Mio. | 24,38 Mio. | 26,37 Mio. | 18,27 Mio. | 46,98 Mio. |
| EV/EBITDA | -465,7 | 33,0 | -140,9 | 14,2 | 77,3 |
| Eigenkapitalrendite | −24,6 % | 0,2 % | −21,5 % | −7,2 % | −87,0 % |
| Kapitalrendite (ROIC) | −6,7 % | 0,0 % | −5,6 % | 6,7 % | 0,0 % |
| Free-Cashflow-Rendite | 0,3 % | −0,5 % | 2,1 % | −9,7 % | −0,9 % |
Wachstum
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Umsatz | −6,0 % | +13,3 % | +9,7 % | +15,7 % | +3,2 % |
| Bruttogewinn | −62,9 % | +17,2 % | +17,3 % | +9,6 % | +5,1 % |
| Operatives Ergebnis | −13.955,8 % | +100,9 % | −184,6 % | +35.560,2 % | −99,9 % |
| Nettogewinn | −10.690,2 % | +101,0 % | −179,7 % | +86,9 % | −7,3 % |
| Gewinn je Aktie | 0,0 % | +100,0 % | −183,3 % | +88,0 % | +2,0 % |
| Freier Cashflow | +204,3 % | −119,0 % | +126,8 % | −340,3 % | −132,2 % |
| Dividende je Aktie | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
Analysten
Einstufungen
Gerade nicht verfügbar.
Kursziel
Gerade nicht verfügbar.
Quartalszahlen
| Aug. 2026 | Mai 2026 | März 2026 | Nov. 2025 | Aug. 2025 | Mai 2025 | März 2025 | Nov. 2024 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | – | – | – | – | – | – | – | – |
| Gewinn je Aktie · Tatsächlich | -0,00 | -0,00 | -17,24 | -0,00 | -0,00 | -0,00 | 0,00 | 0,00 |
| Abweichung | – | – | – | – | – | – | – | – |
| Umsatz · Tatsächlich | 2,67 Mio. | 2,38 Mio. | 2,9 Mio. | – | 3,66 Mio. | 3,24 Mio. | 3,9 Mio. | 3,92 Mio. |
Dividenden und Splits
Keine Dividenden gezahlt.
Aktiensplits
–
Eigentümer
Institutionen
Q2 2026 · 13F
- Anteil institutioneller Investoren
- 0,00 %
- Investoren mit 13F-Meldung
- 1
Größte Investoren
- CAPITAL SQUARE, LLC0,00 %20.000
Insider-Geschäfte
- GROSSO CHRISTOPHER G26. Juni 2026 · director, 10 percent owner: Kauf0 Aktien · 0,07
- Atcher Robert10. Okt. 2025 · directorKauf250.000 Aktien
- Laflin Steve10. Okt. 2025 · directorKauf500.000 Aktien · 0,06
- GROSSO CHRISTOPHER G10. Okt. 2025 · director, 10 percent owner: Kauf500.000 Aktien · 0,06
- Bagerdjian Shahe9. Okt. 2025 · director, officer: Pres. & CEOKauf37,5 Mio. Aktien
- Bagerdjian Shahe22. Mai 2025 · director, officer: Pres. & CEOKauf140.000 Aktien · 0,05
- GROSSO CHRISTOPHER G17. Feb. 2025 · director, 10 percent owner: Kauf269.999 Aktien
- GROSSO CHRISTOPHER G17. Feb. 2025 · director, 10 percent owner: Kauf230.769 Aktien
Vergleichbare Unternehmen
ATNMActinium Pharmaceuticals, Inc.1,59+1,27 %
CATXPerspective Therapeutics, Inc.0,8252+4,93 %
IRMDIRadimed Corporation86,58−0,16 %
ITOCiTonic Holdings Ltd.2,15+6,97 %
MIRMirion Technologies, Inc.17,70−8,10 %
PESIPerma-Fix Environmental Services, Inc.15,93+2,97 %
RADXRadiopharm Theranostics Limited0,82−2,73 %
SRTSSensus Healthcare, Inc.3,41+3,33 %
Über das Unternehmen
Radnostix, Inc. (INIS) is a company that specializes in the global manufacturing and sale of crucial nuclear medicine calibration and reference standards, cobalt-60 products, and offers contract services for producing radiopharmaceuticals and radiochemicals. Its operations are structured into five key divisions: Nuclear Medicine Standards, Cobalt Products, Radiochemical Products, Radiological Services, and Fluorine Products. The Nuclear Medicine Standards segment is responsible for creating various sources and standards essential for single photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging, accurate patient positioning, and for calibrating or testing the performance of dose-measuring equipment within the nuclear pharmacy industry. This segment's product range includes flood sources, dose calibrators, rod sources, flexible and rigid rulers, precision spot and pen point markers, and numerous custom-designed items. The Cobalt Products division processes bulk cobalt, fabricates cobalt capsules for use in radiation therapy and diverse industrial applications, and is involved in the recycling of depleted cobalt sources. Through its Radiochemical Products segment, Radnostix develops and supplies a variety of highly pure radiochemicals, along with the generic drug product sodium iodide I-131, serving medical, industrial, and research applications. The Radiological Services segment offers specialized services such as the safe disposal of flood sources and the intricate processing of gemstones. Finally, the Fluorine Products segment focuses on producing small-scale, high-purity fluoride gas samples for qualification in various industrial applications. It also undertakes the development of critical laboratory and analytical processes required to support a planned uranium de-conversion and fluorine extraction facility. Radnostix, Inc. distributes its products directly to end-users as well as through a network of distributors. The company was founded in 1995 and is headquartered in Idaho Falls, Idaho.
Führung
- Shahe BagerdjianPresident,Chief Executive Officer & Director
- W. Matthew CoxChief Financial Officer & Secretary
- CEO
- Shahe Bagerdjian
- Mitarbeitende
- 45
- Hauptsitz
- Idaho Falls, ID, US
- Sektor
- Healthcare
- Branche
- Drug Manufacturers - Specialty & Generic
- Börsengang
- 14. Aug. 1997
- Website
- radnostix.com
Nachrichten
- PRNewsWire · 19. Okt., 8:05Radnostix and NANO Nuclear Energy Announce Joint Submission of Letter of Intent to NRC Seeking Consent for Transfer of License SUB-1011, Following Lea County Approval of Property LOI
- Defense World · 7. Okt., 3:01International Isotopes (OTCMKTS:INIS) Share Price Crosses Below 200-Day Moving Average – Should You Sell?
- PRNewsWire · 1. Okt., 8:30Radnostix Signs Definitive Agreement to Divest DUF6 and Fluorine Assets to NANO Nuclear
- PRNewsWire · 13. Aug., 11:02Radnostix, Inc. Reports FY2026 2nd Quarter and Six Months Results - Completes Execution of FDA 483 & Recall Actions, Restores Capsule Inventory, Completes Lucerno Dynamics Asset Acquisition
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.